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The novel Coronavirus Disease 2019 (COVID-19) pandemic is having a profound impact on
global healthcare. Shortages in staff, operating theatre space and intensive care beds has
led to a significant reduction in the provision of surgical care. Even vascular surgery, often
insulated from resource scarcity due to its status as an urgent specialty, has limited capacity
due to the pandemic. Furthermore, many vascular surgical patients are elderly with multiple
comorbidities putting them at increased risk of COVID-19 and its complications. There is an
urgent need to investigate the impact on patients presenting to vascular surgeons during the
COVID-19 pandemic.
Methods and analysis
The COvid-19 Vascular sERvice (COVER) study has been designed to investigate the
worldwide impact of the COVID-19 pandemic on vascular surgery, at both service provision
and individual patient level. COVER is running as a collaborative study through the Vascular
and Endovascular Research Network (VERN), an independent, international vascular
research collaborative with the support of numerous national and international organisa-
tions). The study has 3 ‘Tiers’: Tier 1 is a survey of vascular surgeons to capture longitudinal
changes to the provision of vascular services within their hospital; Tier 2 captures data on
vascular and endovascular procedures performed during the pandemic; and Tier 3 will cap-
ture any deviations to patient management strategies from pre-pandemic best practice.
Data submission and collection will be electronic using online survey tools (Tier 1: Survey-
Monkey® for service provision data) and encrypted data capture forms (Tiers 2 and 3: RED-
Cap® for patient level data). Tier 1 data will undergo real-time serial analysis to determine
longitudinal changes in practice, with country-specific analyses also performed. The
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Introduction
The novel coronavirus disease 2019 (COVID-19) pandemic is having an unprecedented effect
on the provision of healthcare services worldwide. The delivery of surgical care to patients dur-
ing this time is suffering as resources dwindle and hospital services are overwhelmed [1, 2]. It
is essential to document the effect of this pandemic on the provision of vascular surgical ser-
vices and the outcomes for vascular patients to guide future guidelines and provide foresight
for potential problems beyond the pandemic.
Vascular patients are, for the majority, considered high risk for respiratory compromise
and subsequent mortality if they contract COVID-19 [3, 4]. They are often frail, elderly,
comorbid, and have less respiratory and physiological reserve than many others who contract
the SARS-CoV2 virus [5]. A significant proportion of vascular surgical practice involves per-
forming prophylactic operations to reduce the risk of a future cardiovascular event, for exam-
ple carotid endarterectomy to prevent stroke or abdominal aortic aneurysm repair to prevent
rupture. In addition, urgent or emergency surgical intervention to prevent the loss of limb or
life, often through an endovascular and/or open revascularisation procedure, are
commonplace.
Given the complex nature of vascular operations and the equally complex and co-morbid
patient population, the COVID-19 pandemic presents a particularly challenging situation for
the vascular surgeon. There is a delicate balance between the risk of a patient contracting or
surviving COVID-19, the availability of critical care and anaesthetic support needed to per-
form high-risk vascular interventions, and the risk of limb loss, other significant morbidity or
mortality for the patient from their presenting condition if treatment is unduly delayed.
A major curtailment of vascular practice has already occurred, with many vascular institu-
tions postponing all but the most urgent surgery, choosing and endovascular surgical option
where feasible, delaying routine clinic appointments, and using telephone consultations much
more frequently [6]. Given the unparalleled nature of the situation, there is an urgent need to
quantify the impact of COVID-19 on the provision of vascular surgical services, the adjust-
ments made to vascular practice, and the consequence to patient care.
The COvid-19 Vascular sERvice (COVER) Study is a three-tiered study designed to capture
global data on vascular practice(s) during the pandemic including how practice evolves over
time, the effect on outcomes for patients presenting with, and/or receiving treatment for, vas-
cular surgical conditions during the pandemic and in the subsequent months of global
recovery.
Study overview
COVER will be run as a worldwide collaborative research project. It will be led by the UK-
based Vascular and Endovascular Research Network (VERN). VERN is an established inde-
pendent, international vascular trainee research collaborative, which has previously designed
and delivered several projects across the UK and internationally [7, 8].
The aims of the study are to understand and evaluate the impact of the COVID-19 pan-
demic on global vascular practice.
Centres and individuals will be invited to participate in the COVER study which will be
advertised via VERN social media channels as well as via regional VERN representatives
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(doctors, nurses and other healthcare professionals) and through our collaborative networks
mailing lists. Engagement with each tier of the project by each collaborator is anticipated and
outlined below.
Materials and methods
The study has 3 ‘Tiers’:
Tier 1 is a survey of vascular surgeons to capture longitudinal changes to the provision of
vascular services within their hospital.
Tier 2 will capture data on vascular and endovascular procedures performed during the
pandemic.
Tier 3 will capture management of referrals made to vascular teams, focusing on any devia-
tions to patient management strategies from pre-pandemic best practice.
Centre eligibility
All hospitals and networks which provide cover for elective and emergency vascular patients.
Tier 1—Changes to unit-level clinical processes
Primary objective. To objectively capture the changes made to the structure and delivery
of vascular surgery at unit level throughout the COVID-19 pandemic.
Secondary objective. International comparison of structural changes made to vascular
practice.
Outcomes. Primary Outcome. Documentation of changes to structure and activities and
processes within vascular services during the first peak of COVID-19 globally., including:
• Operations/interventions offered/not offered
• Thresholds for offering admission/intervention
• Seniority and/or number of specialists performing caseload
• Management of screening / surveillance programmes (AAA, post-EVAR, bypass graft sur-
veillance, stent surveillance)
• Imaging availability
• Interventional radiology support and availability
• Management of multi-disciplinary team meetings
• Changes to trainee (resident/registrar) and consultant/attending rotas
• Outpatient clinic availability and format
• Use of vascular team members to cross-cover other specialties or clinical areas
• The availability of personal protective equipment (PPE)
Secondary outcomes. International comparison of changes made to vascular services, and
documentation of how practice fluctuates as case numbers rise and fall using a surgeon derived
scoring system.
Materials and methods
The Tier 1 “service evaluation study” will be circulated to all interested centres and data col-
lected via an online survey platform (SurveyMonkey1). This will be conducted upon each
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centre registering to participate in the overall study bundle. This survey will be repeated at reg-
ular intervals to document ongoing changes to unit practice in response to changing circum-
stances. The intervals between the survey repeats will depend upon the progress of the
pandemic. Collaborators will be updated regularly regarding survey outcomes. Responses will
reflect unit practice as a whole and should therefore be a unified unit level response approved
by the centre lead.
This information will be fed back to the relevant bodies (VSGBI, ESVS, SVS etc.) to allow
real-time feedback on practicalities of updated guidelines. The information will also be circu-
lated via social media.
International/continental comparisons will be performed, where possible, to describe rela-
tive change in practice. A score of 0 to 3 will be allocated to each answer based on perceived
relative service reduction by 12 VERN healthcare-professionals (‘0’ representing no change,‘3’
representing most significant change; S2 File).
Tier 2 –Vascular and endovascular procedural data capture
Primary objective. To capture data on all vascular and endovascular interventions being
undertaken throughout the COVID-19 pandemic and report early and late outcomes.
Secondary objective. Comparison of short and long-term clinical outcomes for patients
receiving a procedure during the COVID-19 pandemic and those operated on during time
periods not impacted by the pandemic.
Outcomes. Primary outcome. Data demonstrating volume and types of vascular interven-
tions performed during the pandemic. Specifically:
• Types of procedure performed
• Time taken from presentation to intervention
• Mode of referral (primary vs. secondary care)
• Site of surgery: hub or spoke hospital
• Imaging modalities used and timings
• UK National Confidential Enquiry into Patient Outcome and Death (NCEPOD)
classification
• Operative technique(s) and device(s) used
• Mode(s) of anaesthesia
• Time to discharge
• Whether suspected or confirmed COVID-19 +ve at time of surgery, COVID-19 +ve after
surgery, or COVID-19 -ve
• Documentation of changes to usual practice (type of procedure, type of anaesthetic, post-
procedural destination)
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• Disease-specific mortality
• Morbidity
• If COVID-19 +ve: respiratory outcome, admission to intensive care unit.
Any type of re-admission will be included during the follow-up in the clinical team consider
it is linked to index procedure. Morbidity will be defined by condition specific complications
and generic surgical and medical complications in the clinical report forms. A preliminary list
of outcomes to be measured at six months and one year have been included in the (S1 File).
Materials and methods
This will be undertaken for a 3-month period in the first instance. This time period is subject
to change depending on how the pandemic progresses.
Patient enrolment
Patients will be identified prospectively at the time of surgery. To ensure comprehensive data
capture, patients may also be identified retrospectively following an emergency procedure for
example. All patients receiving a vascular procedure are eligible for enrolment, including
COVID-19 positive (+ve), COVID-19 suspected and COVID-19 negative (-ve). Inclusion and
exclusion criteria will be specific to each country, due to the variation in approval processes
internationally. However, broadly speaking:
Inclusion criteria. Any patient over the age of 18 undergoing an operation or procedure for
a recognised vascular condition, including trauma. This includes patients who died on table
during the procedure.
Exclusion criteria. Any procedure initially thought to require a vascular intervention which
then did not e.g. laparotomy for suspected abdominal aortic aneurysm for which an alternative
pathology was found. The requirement for patient consent for inclusion in the study will be
approached on a centre by centre (or country by country basis).
Tier 3 –Changes to acute vascular care management
Primary objective. To capture modification to the management of all referred urgent
vascular cases during the COVID-19 pandemic and identify deviations from pre-pandemic
best practice, standards and/or guidelines for acute/urgent cases due to healthcare pressures or
resource limitations. This will focus on (but not be limited to) chronic limb-threatening
ischaemia, symptomatic carotid disease, acute aortic syndromes and aortic aneurysmal
disease.
Secondary objective. Linkage of data on change in practice to clinical outcomes at 6 and
12 months.
Outcomes. Primary outcome. Documentation of deviation from “best vascular practice”
and the impact on patient care This will specifically focus on:
• Chronic Limb Threatening Ischaemia (CLTI) [9]:
� Decision to discharge, admit or refer to an emergency (‘hot’) clinic
� Decision for endovascular- or open surgical revascularisation first strategy
� Decision for best medical therapy, palliation or primary amputation
• Symptomatic carotid disease:
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� Patients managed with best medical therapy (BMT)
� Modifications to the indication and decision for carotid endarterectomy (CEA)
� Delays to treatment due to lack of resources, including operating theatre, anaesthetic sup-
port or bed availability
• Abdominal Aortic Aneurysm (AAA):
� Use of endovascular repair +/- local anaesthesia
� Changes to criteria for intervention
� Decisions for palliation, i.e. ‘turn down’
• Acute Aortic Syndrome (AAS):
� Decision to manage in non-critical care beds
� Changes to imaging protocol at unit level
� Decision to defer intervention
Secondary Outcomes. Outcome measures at 6 and 12 months. Comparison of these out-
comes with patients without change to management during the pandemic.).
• Example condition-specific outcome measures to include:
� CLTI: limb salvage, amputation free survival, all-cause mortality
� Carotid disease: ipsilateral stroke rate, any stroke rate, all-cause mortality
� AAA: aneurysm-related mortality, all-cause mortality
• AAS: complication rate including rupture, all-cause mortalityOther vascular presentations
such as via MDT, hot-foot clinic referrals.
Any type of re-admission will be included during the follow-up in the clinical team consider
it is linked to index referral. Morbidity will be defined by condition specific complications and
generic surgical and medical complications in the clinical report forms. A preliminary list of
outcomes to be measured at six months and one year have been included in the (S1 File).
Materials and methods. This will take place over a minimum of one month and will
invite vascular specialists to complete an anonymised proforma for every patient with any of
the conditions listed above referred to the vascular service. Timings may change based on the
duration of the pandemic.
Patient enrolment. Patients will be identified prospectively at the time of referral to the
vascular team. To ensure comprehensive data capture, patients may also be identified retro-
spectively. All patients referred to vascular services are eligible for enrolment, including
COVID-19 +ve, COVID-19 suspected and COVID-19 -ve. As for tier 2, inclusion and exclu-
sion criteria will be specific to each country.
Inclusion criteria. Any patient over the age of 18 referred to the vascular team for a recog-
nised vascular condition.
Exclusion criteria. Any patient initially thought to have a vascular condition requiring a vas-
cular team review, which was subsequently found not to be a vascular condition e.g. a referral
for abdominal pain? ruptured aortic aneurysm in a patient subsequently found to not have a
AAA and another pathology instead. As with tier 2, the requirement for patient consent for
inclusion in the study will be approached on a centre by centre (or country by country basis).
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Tier 2 and tier 3 data collection
Tier 2 and Tier 3 data (all anonymised and non-identifiable) will be collected and stored
through a secure UK National Health Service server using the Research Electronic Data Cap-
ture (REDCap) web application. Designated collaborators at each participating site will be pro-
vided with REDCap project server login details, allowing them to securely submit data on to
the REDCap system. REDCap has previously been successfully used for a range of other inter-
national cohort studies, including those led by GlobalSurg and the European Society of Colo-
proctology. The REDCap server is managed by the University of Birmingham, UK, with
support provided by the GlobalSurg team.
Anonymised data will be collected relating to COVID-19 status, comorbidities, physiologi-
cal state, treatment, operation or intervention, and outcome. A unique identifier will be
assigned to each patient record. All participating centres will keep a record of patient details
relating to the unique identifier for the collection of medium- and long-term outcome data
and linking to the original participant record on REDCap
Analyses
As this is a non-interventional study, analysis will be limited to presentation of numbers and
proportions, with comparisons made to national and international standards. Interim analyses
will be performed periodically to inform data collection and provide up to date information
on the impact of the pandemic. The first formal analysis for Tier 2 will be performed once 50
patients have been entered onto the database, and the frequency of subsequent analyses will be
determined by the findings of this. Hospital-level data will not be released or published by the
VERN team, but individual centres will have full access to their own data.
National and local approvals
Ethical approval from the UK Health Research Authority has been obtained for Tiers 2 and 3,
permitting the capture of patient outcomes at 6 and 12 months (20/NW/0196 Liverpool Cen-
tral, IRAS: 282224). The study is registered with ISRCTN registry (80453162).
Participating centres in the UK will be required to seek local research and development
approval. Non-UK centres will need to obtain a research ethics committee or institutional
review board approval in accordance with national and/or local requirements. The principal
investigator at each participating site is responsible for obtaining necessary local approvals.
Study organisational sponsorship is through the R&D Department at University Hospitals,
Coventry and Warwickshire NHS Trust, Coventry, UK.
Authorship
Collaborators from each site who contribute patients will be recognised on any resulting publi-
cations as PubMed-citable co-authors. The VERN model for collaborative authorship, that will
be used for any disseminations arising from this project can be found here: https://vascular-
research.net/authorship-policy/. An example of this can be found here: https://pubmed.ncbi.
nlm.nih.gov/29452941).
Discussion
The COVER study has been designed as the first vascular trainee led, multi-national prospec-
tive study of Vascular Surgical practice during the COVID-19 pandemic. It has several key
points that will make it increasingly relevant in the current climate. A high mortality has been
reported in elective general surgery patients who are COVID positive [10], which is
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concerning for the vascular patient population who are at increased risk of succumbing to a
COVID-19 infection owing to their older age, high levels of smoking and background respira-
tory conditions, and comorbidities including diabetes. These factors have all been linked to
significantly reduced rates of survival in those that have contracted the SARS-CoV2 virus. Pre-
existing conditions also mean that if our patients are admitted to hospital, they are less likely to
be considered candidates for invasive ventilation due to the associated mortality reported [11].
In addition, COVID-19 associated coagulopathy is emerging as a presenting complaint for
COVID-19 infection and will impact on vascular been observed; however it is unclear if this is
a reduction in self-referrals to primary care due to fear of coming into hospital, or gatekeeping
being performed by referring teams.
There is a familiarity within vascular surgery with the consequences of delays in presenta-
tion for key conditions such as acute aortic pathologies and CLTI, leading to fewer treatment
options and poorer prognosis. As the pandemic progresses and elective operating is curtailed
or stopped completely, there will be a growing list of patients who will require urgent surgery
in the post-pandemic period once ‘normal’ service has resumed. This study will address the
consequence of delaying surgery considered urgent or essential, and an understanding of the
vascular caseload volume that is accumulating during the pandemic period that will need to be
appropriately managed once the crisis has passed.
Through well-structured and purposeful collaborative working the VERN group developed
and submitted the COVER study for ethical approval. This has been granted promptly to facili-
tate COVID-19 related research within vascular surgery. Similarly, the global vascular commu-
nity has responded positively and over 150 centres have already participated in Tier 1 and
registered interest for the other tiers across the globe indicating the support and global appeal
of the study.
VERN and the COVER study has a strong trainee focus with the opportunity for trainees to
contribute high quality data from their own centres. From previous work we have been able to
demonstrate that trainees are highly motivated to participate in research when their efforts are
recognised and PubMed citable [12]. This has been echoed by global collaborative studies such
as those run by GlobalSurg [13] (https://globalsurg.org/), conducted under a single author
name and listing all those individuals who have contributed as co-authors.
The protocol has been designed with the support of the Vascular Society of Great Britain
and Ireland, who recognise the value and importance of accurate data collection during this
period. The study data collection tools have been developed in close co-operation with our col-
leagues in Europe, the USA and Australia, to ensure questions are applicable and that possible
answers reflect variations in practice around the globe. It has also helped to ensure that infor-
mation is collected in sufficient depth to correlate with key outcomes at 6 and 12 months, with-
out being onerous.
The study also benefits from the ongoing public dissemination of international vascular
guidelines to support clinicians managing the current COVID-19 crisis. This will enable com-
parison of real time changes in practice against emerging and evolving guidelines. Further-
more, the availability of various national registries, that have benchmarked ‘normal’ practice
and ‘expected’ condition-specific outcomes for key parameters against which there can be a
detailed comparison of COVER study-reported practices and outcomes. Data points relating
to patient, technical and peri-operative variables will also be compared between countries and
wider regions to explore how differences in populations and practice may impact on disease
specific outcomes at 6 and 12 months.
Tier 1 has already collected valuable real-time data which has been used to inform those
who create and disseminate national guidelines [14]. Promoting inclusion amongst the global
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vascular trainee community will also play a role in professional development, research skills
and achievements which would not otherwise be available.
Study limitations
COVER is a pragmatic real-world study. The nature of the current pandemic has meant that
an appropriate sample size is difficult to calculate. Additionally, the dynamic nature of the
COVID-19 pandemic means that numbers of cases, including those testing positive for or sus-
pected to have infection with the SARS-CoV2 virus—hence a denominator for some calcula-
tions—are unknown. This insurmountable problem is not limited to this study and is
currently frustrating efforts to determine appropriate strategies for lifting the lockdown in
countries where the peak of the pandemic appears to have passed.
Many countries have scaled back elective practice and changed thresholds for operating on
carotid stenosis and aortic aneurysms to varying degrees and along different timelines due to
resource scarcities. This will have an impact on the volume of cases uploaded into Tier 2 and
Tier 3 of the study, but the concurrent completion of Tier 1 should reflect this and has already
provided live data from over 150 institutions in 45 countries across the globe. In the first
instance, country-specific experiences have been shared to highlight practice changes around
the globe with vascular colleagues. This information will also be used when analysing country-
specific trends for surgery and referrals. This will allow inclusion of important variables such
as type of hospital (private or government-run), loss of specialty firms with the redeployment
of staff to support other specialties; the exact timing for milestones such as stopping screening
programmes for aortic aneurysm, or moving to a practice of mainly best medical therapy for
symptomatic carotid artery stenosis.
Conclusion
Success of the COVER study will provide the global vascular community with robust data on
the impact of the COVID-19 pandemic on our patients and the future legacy of delayed sur-
gery and adjusted decision making. It will support further collaboration between vascular
trainees globally, bringing together and recognising efforts to collaborate with colleagues
around the world.
Supporting information
S1 File. Preliminary list of condition specific outcomes to be reported at 30 day, 6 and 12
month follow-up.
(DOCX)
S2 File. International/Continental comparison analysis.
(DOCX)
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